SPC Logo

Ketopine (Ketoconazole) 2% w/w Shampoo

Last Updated on eMC 11-Sep-2014 View changes  | Pinewood Healthcare Contact details

1. Name of the medicinal product

Ketopine (Ketoconazole) 2% w/w Shampoo

Ketoconazole 2% w/w Shampoo

2. Qualitative and quantitative composition

Each gram of shampoo contains 20 milligrams of Ketoconazole.

For a full list of excipients, see Section 6.1.

3. Pharmaceutical form

Shampoo

Clear, pink, viscous solution.

4. Clinical particulars
4.1 Therapeutic indications

Ketopine (Ketoconazole) shampoo 2% is indicated for the treatment and prevention of seborrhoeic dermatitis, pityriasis capitis (dandruff) and pityriasis versicolor that may be associated with the fungus Pityrosporum.

4.2 Posology and method of administration

For topical administration.

Adults including the elderly and adolescents:

Wet hair and scalp thoroughly with water.

Apply sufficient shampoo to produce enough lather to wash the scalp and hair, gently massage it over the entire scalp and leave for 3-5 minutes before rinsing thoroughly.

Seborrhoeic dermatitis and dandruff: Use Ketopine (Ketoconazole) shampoo 2% twice weekly for 2-4 weeks.

Prophylaxis: Use Ketopine (Ketoconazole) shampoo 2% once every 1-2 weeks

Pityriasis versicolor: Use Ketopine (Ketoconazole) shampoo 2% once daily for a maximum of 5 days.

Prophylaxis: As patches of pityriasis versicolor become more apparent on exposure to the sun. Ketopine (Ketoconazole) shampoo 2% may be used once daily for a maximum of 3 days in a single treatment course before exposure to sunshine.

4.3 Contraindications

Hypersensitivity to ketoconazole or any of the excipients.

4.4 Special warnings and precautions for use

In patients who have been on prolonged treatment with topical corticosteroids, it is recommended that the steroid therapy be gradually withdrawn over a period of 2 – 3 weeks, while using Ketopine (Ketoconazole) Shampoo 2%, to prevent any potential rebound effect.

Ketopine (Ketoconazole) Shampoo 2% may be irritating to mucous membranes of the eyes and contact with this area should be avoided. If Ketopine (Ketoconazole) Shampoo 2% does get into the eyes, they should be bathed gently with cold water.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed

4.6 Pregnancy and lactation

Ketopine (Ketoconazole) is not detected in plasma after chronic shampooing or topical application.

Ketopine (Ketoconazole) is not contraindicated for pregnancy or lactation, but caution should be exercised.

4.7 Effects on ability to drive and use machines

Not relevant

4.8 Undesirable effects

The safety of Ketoconazole 2% Shampoo was evaluated in 2980 subjects who participated in 22 clinical trials. Ketoconazole 2% Shampoo was administered topically to the scalp and/or skin. Based on pooled safety data from these clinical trials, there were no ADRs reported with an incidence ≥ 1%.

The following table displays ADRs that have been reported with the use of Ketoconazole 2% Shampoo from either clinical trial or postmarketing experiences.

The displayed frequency categories use the following convention:

Very common ≥ 1/10

Common ≥ 1/100 and < 1/10

Uncommon ≥ 1/1,000 and <1/100

Rare ≥ 1/10,000, <1/1,000

Very rare <1/10,000, including isolated reports

Not known (cannot estimate from the available clinical trial data).

System Organ Class

Adverse Drug Reactions

Frequency Category

Uncommon

(≥1/1,000 and <1/100)

Rare

(≥1/10,000 and <1/1,000)

Not Known

Immune System Disorders

 

Hypersensitivity

 

Nervous System Disorders

 

Dysgeusia

 

Infections and Infestations

Folliculitis

  

Eye Disorders

Increased lacrimation

Eye irritation

 

Skin and Subcutaneous Tissue Disorders

Alopecia

Dry Skin

Hair texture abnormal

Rash

Skin burning sensation

Acne

Dermatitis contact

Skin disorder

Skin exfoliation

Angioedema

Urticaria

Hair colour changes

General Disorders and Administration Site Conditions

Application site erythema

Application site irritation

Application site pruritus

Application site reaction

Application site hypersensitivity

Application site pustules

 

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

4.9 Overdose

In the event of accidental ingestion, supportive and symptomatic measures should be carried out. In order to avoid aspiration, neither emesis nor gastric lavage should be instigated.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic (ATC) Classification: D01A C08

Ketoconazole is a synthetic imidazole-dioxalane derivative. It is a broad spectrum antifungal agent which inhibits the growth of common dermatophytes and yeasts by altering the permeability of the cell membrane:

Dermatophytes: Trichophyton rubrum, T. mentagrophytes, T.tonsurans, Microsporum canis, M. audouini, M. gypseum and Epidermophyton floccosum.

Yeasts: Candida albicans, C tropicalis, Pityrosporum ovale (Malassezia ovale) and Pityrosporum orbiculare (M. furfur).

5.2 Pharmacokinetic properties

Ketoconazole was not detected in plasma in 39 patients who shampooed 4-10 times per week for 6 months or in patients who shampooed 2-3 times per week for 3-26 months. Twelve hours after a single shampoo, hair samples taken from six patients showed that high amounts of ketoconazole were present on the hair; only about 5% had penetrated into the hair keratin. There were no detectable plasma levels after chronic shampooing twice weekly for two months with ketoconazole.

5.3 Preclinical safety data

There is no relevant information additional to that contained elsewhere in the Summary of Product Characteristics.

6. Pharmaceutical particulars
6.1 List of excipients

Sodium Laureth Sulfate Paste 70 %

Disodium Laureth Sulfosuccinate Liquid 40%

Sodium Chloride

Citric Acid Monohydrate

Benzyl Alcohol

Tetrasodium EDTA

Quaternium-15

Polyquaternium-7

Dexpanthenol

Laureth-2

Sodium Hydroxide

Erythrosine (E127)

Perfume

Purified water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

27 months

6.4 Special precautions for storage

Do not store above 25 °C.

Store in original container.

Keep container tightly closed.

6.5 Nature and contents of container

White High-density polyethylene (HDPE) multi dose bottles with Polypropylene flip top closures.

Pack sizes: 120 ml.

6.6 Special precautions for disposal and other handling

Not applicable.

7. Marketing authorisation holder

Pinewood Laboratories Limited trading as Pinewood Healthcare

Ballymacarbry,

Clonmel,

Co. Tipperary,

Ireland

8. Marketing authorisation number(s)

PL 04917/0039

9. Date of first authorisation/renewal of the authorisation

09/02/2009

10. Date of revision of the text

09/07/2014

Company contact details

Pinewood Healthcare

Company image
Address

Ballymacarby, Clonmel, Co. Tipperary, Co. Tipperary, Ireland

Fax

+ 353 52 6136311

Medical Information e-mail
Telephone

+353 52 6186000

Medical Information Direct Line

+44 1978 661 261

Medical Information Fax

+44 1978 661 702

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

ketoconazole

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue